Heewoong Yoon
Heewoong Yoon has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Jiwon Seo
Department of Chemistry, Gwangju Institute of Science and Technology, Gwangju 61005, Republic of Korea
3 shared publications Jieun Choi
Department of Chemistry
2 shared publications- Jung-Hyun Lee
Korea University
2 shared publications Byeongkwon Kim
Department of Bioscience and Biotechnology
1 shared publicationChae Yeong Lee
Department of Bioscience and Biotechnology
1 shared publication- Chul-Seung Park
Gwangju Institute of Science and Technology (GIST)
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 26 February 2026
- Published by American Chemical Society (ACS) in Nano Letters
- Vol. 26 (9) , 3003-3011
Modulation of Peptoid Nanostructure for Antibiofilm Hydrogel Interfaces
Most hospital-acquired infections originate from bacterial biofilms on implantable devices, where the extracellular polymeric substance (EPS) matrix protects microbes and promotes multidrug resistance (MDR). Preventing biofilm initiation, particularly bacterial adhesion and proliferation, offers an effective strategy to combat device-associated infections. However, developing biocompatible materials that combine antimicrobial and antiadhesive functions remains a challenge. Herein, we present a strategy to engineer antibiofilm hydrogels by incorporating antimicrobial peptoids (ampetoids) into a gelatin-based matrix with controlled supramolecular organization. By tuning the stoichiometric ratio between thiol-functionalized ampetoids and norbornene groups in the matrix, we controlled peptoid nanostructure within the hydrogel, where suppression of peptoid self-assembly proved critical for balancing antimicrobial activity, antiadhesive properties, and cytocompatibility. This molecular-level control enabled the hydrogels to inhibit biofilm formation by S. aureus and P. aeruginosa. These results highlight regulation of peptoid self-assembly within hydrogels as a promising approach for designing multifunctional antibiofilm coatings for contamination-prone medical devices.
- 26 February 2026
- Published by American Chemical Society (ACS) in Nano Letters
- Vol. 26 (9) , 3003-3011
Top Cited PapersOpen AccessModulation of Peptoid Nanostructure for Antibiofilm Hydrogel Interfaces
Most hospital-acquired infections originate from bacterial biofilms on implantable devices, where the extracellular polymeric substance (EPS) matrix protects microbes and promotes multidrug resistance (MDR). Preventing biofilm initiation, particularly bacterial adhesion and proliferation, offers an effective strategy to combat device-associated infections. However, developing biocompatible materials that combine antimicrobial and antiadhesive functions remains a challenge. Herein, we present a strategy to engineer antibiofilm hydrogels by incorporating antimicrobial peptoids (ampetoids) into a gelatin-based matrix with controlled supramolecular organization. By tuning the stoichiometric ratio between thiol-functionalized ampetoids and norbornene groups in the matrix, we controlled peptoid nanostructure within the hydrogel, where suppression of peptoid self-assembly proved critical for balancing antimicrobial activity, antiadhesive properties, and cytocompatibility. This molecular-level control enabled the hydrogels to inhibit biofilm formation by S. aureus and P. aeruginosa. These results highlight regulation of peptoid self-assembly within hydrogels as a promising approach for designing multifunctional antibiofilm coatings for contamination-prone medical devices.
- 19 September 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (19) , 20283-20303
Therapeutic Potential of Novel Antimicrobial Peptide Pap12-6-10: Mechanisms of Antibacterial and Anti-inflammatory Action Against Gram-Negative Sepsis
To develop novel antibiotics, we engineered 12-mer peptides derived from the N-terminus of papiliocin. Pap12-6-10 emerged as a potent antibacterial agent against multidrug-resistant Gram-negative bacteria, demonstrating a low propensity for resistance development. Pap12-6-10 exerts its antibacterial activity by permeabilizing bacterial membranes through binding to lipopolysaccharide (LPS), inducing oxidative stress that leads to cell death. Pap12-6-10 modulates LPS-induced inflammatory responses by selectively targeting the TLR4 signaling pathways. Structural analysis using NMR, surface plasmon resonance, docking, and molecular dynamics simulations suggested that Pap12-6-10 binds to the hydrophobic pocket of MD-2, thereby preventing the LPS-induced dimerization of the TLR4/MD-2 complex, which is essential for inflammatory signaling during sepsis. In the Escherichia coli K1 and carbapenem-resistant Acinetobacter baumannii-induced sepsis mouse model Pap12-6-10 protected organ damage from septic shock and displayed significant therapeutic effects while maintaining low cytotoxicity. This study highlights its potential as a valuable candidate for treating Gram-negative infections.
- 19 September 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (19) , 20283-20303
Therapeutic Potential of Novel Antimicrobial Peptide Pap12-6-10: Mechanisms of Antibacterial and Anti-inflammatory Action Against Gram-Negative Sepsis
To develop novel antibiotics, we engineered 12-mer peptides derived from the N-terminus of papiliocin. Pap12-6-10 emerged as a potent antibacterial agent against multidrug-resistant Gram-negative bacteria, demonstrating a low propensity for resistance development. Pap12-6-10 exerts its antibacterial activity by permeabilizing bacterial membranes through binding to lipopolysaccharide (LPS), inducing oxidative stress that leads to cell death. Pap12-6-10 modulates LPS-induced inflammatory responses by selectively targeting the TLR4 signaling pathways. Structural analysis using NMR, surface plasmon resonance, docking, and molecular dynamics simulations suggested that Pap12-6-10 binds to the hydrophobic pocket of MD-2, thereby preventing the LPS-induced dimerization of the TLR4/MD-2 complex, which is essential for inflammatory signaling during sepsis. In the Escherichia coli K1 and carbapenem-resistant Acinetobacter baumannii-induced sepsis mouse model Pap12-6-10 protected organ damage from septic shock and displayed significant therapeutic effects while maintaining low cytotoxicity. This study highlights its potential as a valuable candidate for treating Gram-negative infections.
- Open Access
- 23 October 2024
- Published by Springer Nature in npj Parkinson's Disease
- Vol. 10 (1) , 1-14
CRBN modulates synuclein fibrillation via degradation of DNAJB1 in mouse model of Parkinson disease
Cereblon (CRBN) is a substrate recruiter for CRL4CRBN E3 ubiquitin ligase system playing a plethora of pivotal roles for biological systems. Here, we identified DNAJB1 (DJ1) as endogenous substrate of CRBN and report how CRBN influences the aggregation and toxicity of alpha-synuclein (α-SYN) via modulation of DJ1. CRBN interferes with molecular activities of DJ1 in vitro, in cells, and in vivo resulting in a reduced disaggregation of α-SYN fibrils, increased formation of preformed fibrils (PFFs) of α-SYN, and high susceptibility of mice to MPTP and PFF-induced neurotoxicity. Depletion of Crbn improves the behavioral and biochemical responses of mice towards neurotoxic insult. Finally, we designed a peptide inhibitor to inhibit the recruitment of DJ1 to CRBN for ubiquitination, resulting in an enhanced supply of DJ1 to counteract the toxicity of aggregated α-SYN. Our data has important implications for development of CRBN-targeting therapies that could prevent or delay progression of neurodegenerative synucleinopathy.
- 23 October 2024
- Published by Springer Nature in npj Parkinson's Disease
- Vol. 10 (1) , 1-14
Open AccessCRBN modulates synuclein fibrillation via degradation of DNAJB1 in mouse model of Parkinson disease
Cereblon (CRBN) is a substrate recruiter for CRL4CRBN E3 ubiquitin ligase system playing a plethora of pivotal roles for biological systems. Here, we identified DNAJB1 (DJ1) as endogenous substrate of CRBN and report how CRBN influences the aggregation and toxicity of alpha-synuclein (α-SYN) via modulation of DJ1. CRBN interferes with molecular activities of DJ1 in vitro, in cells, and in vivo resulting in a reduced disaggregation of α-SYN fibrils, increased formation of preformed fibrils (PFFs) of α-SYN, and high susceptibility of mice to MPTP and PFF-induced neurotoxicity. Depletion of Crbn improves the behavioral and biochemical responses of mice towards neurotoxic insult. Finally, we designed a peptide inhibitor to inhibit the recruitment of DJ1 to CRBN for ubiquitination, resulting in an enhanced supply of DJ1 to counteract the toxicity of aggregated α-SYN. Our data has important implications for development of CRBN-targeting therapies that could prevent or delay progression of neurodegenerative synucleinopathy.
- 18 November 2023
- Published by Elsevier in Chemical Engineering Journal
- Vol. 478
Biomimetic peptoid-assisted fabrication of antibiofouling thin-film composite membranes
- 18 November 2023
- Published by Elsevier in Chemical Engineering Journal
- Vol. 478
Biomimetic peptoid-assisted fabrication of antibiofouling thin-film composite membranes